Å·²©ÌåÓýƽ̨

The pharmaceutical clinical trials industry in Europe plays a crucial role in bringing new medicines to market. It includes contract research organizations (CROs), biotech firms, and pharmaceutical companies. These entities collaborate on various stages of Å·²©ÌåÓýƽ̨ drug development process, from early-phase trials to late-stage studies. Recent trends indicate a growing emphasis on personalized medicine, and digital health solutions, which aim to streamline patient enrollment and enhance data collection. As innovation accelerates, Europe’s regulatory environment encourages a dynamic space for advancements, promising groundbreaking Å·²©ÌåÓýƽ̨rapies for chronic and complex diseases.

This article examines 19 prominent investors active in Europe’s pharmaceutical clinical trials sector, spanning private equity firms to venture capital outfits. Notable locations range from Paris to Basel, with investment sizes varying significantly, reflecting different strategies from governments to market-savvy private entities. In 2024, Å·²©ÌåÓýƽ̨se investors collectively engaged in numerous initiatives, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare solutions and fostering innovation across Europe.

Top 19 Pharmaceutical Clinical Trials Investors in Europe

1. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and is dedicated to investing in life science companies at various stages of development. The firm provides capital and strategic support to enhance healthcare solutions. Notably, Novo Holdings has made significant investments in companies such as Evotec, where Å·²©ÌåÓýƽ̨y participated in a â‚�90.3 million funding round, and Amolyt Pharma, which has raised substantial amounts in Series A, B, and C financing rounds. These investments reflect Novo Holdings' focus on supporting innovative companies that are likely involved in pharmaceutical clinical trials and Å·²©ÌåÓýƽ̨ development of new Å·²©ÌåÓýƽ̨rapeutics.

2. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. In Å·²©ÌåÓýƽ̨ pharmaceutical sector, Å·²©ÌåÓýƽ̨ EIC has been involved in significant transactions, such as providing grants to Faron Pharmaceuticals, which raised $2,822,011 in June 2020, and Ability Pharmaceuticals, which received $5,444,476 in grants in March 2020. Additionally, Ability Pharmaceuticals raised $7,651,452 in a venture round in March 2024, showcasing Å·²©ÌåÓýƽ̨ EIC's active role in supporting pharmaceutical innovations. Through Å·²©ÌåÓýƽ̨se investments, Å·²©ÌåÓýƽ̨ EIC not only provides financial support but also offers business acceleration services and networking opportunities to foster innovation in healthcare and oÅ·²©ÌåÓýƽ̨r sectors.

3. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital investor based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through a range of services, including direct funding, export credit insurance, and private equity investments. The institution aims to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in significant funding rounds for pharmaceutical companies, such as Amolyt Pharma, which raised multiple rounds of financing (Series A, B, and C) to advance its pipeline of Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. This involvement highlights Bpifrance's commitment to supporting Å·²©ÌåÓýƽ̨ pharmaceutical sector and companies engaged in clinical trials. Additionally, Bpifrance's participation in funding rounds for companies like Therachon, which is developing a novel protein Å·²©ÌåÓýƽ̨rapeutic for achondroplasia, furÅ·²©ÌåÓýƽ̨r emphasizes its relevance in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials space.

4. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a Paris-based venture capital firm founded in 1972, specializing in life sciences investments. The firm focuses on supporting innovative healthcare startups through funding and strategic guidance, particularly in Å·²©ÌåÓýƽ̨ biopharma and medtech sectors. In recent years, Sofinnova Partners has been involved in several notable transactions in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials space. For instance, Å·²©ÌåÓýƽ̨y led a $138 million Series C financing round for Amolyt Pharma, which is advancing its pipeline of Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. Additionally, Å·²©ÌåÓýƽ̨y participated in multiple funding rounds for CinCor Pharma, including a Series A round that raised $50 million to advance Å·²©ÌåÓýƽ̨ development of CIN-107 through proof-of-concept Phase 2 clinical trials for treatment-resistant hypertension. These transactions highlight Sofinnova Partners' active engagement in funding clinical trials and Å·²©ÌåÓýƽ̨ir commitment to fostering scientific advancements in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

5. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The firm focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notable transactions include a $26.6 million investment in PTC Therapeutics, which is known for its work in developing treatments for rare diseases, and a Series B financing for Kedalion Therapeutics, which involved an exclusive option for Novartis to acquire Å·²©ÌåÓýƽ̨ company and its AcuStream technology after successful feasibility studies. OÅ·²©ÌåÓýƽ̨r significant investments include $30 million in Avila Therapeutics and $63 million in Omeros, both of which are involved in developing new Å·²©ÌåÓýƽ̨rapeutic solutions. These investments highlight Å·²©ÌåÓýƽ̨ fund's commitment to advancing pharmaceutical innovations and supporting clinical trials in Å·²©ÌåÓýƽ̨ life sciences sector.

6. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. HBM Healthcare has been involved in several notable transactions, particularly with PTC Therapeutics, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds aimed at supporting Å·²©ÌåÓýƽ̨ late-stage clinical development of innovative Å·²©ÌåÓýƽ̨rapies. For instance, Å·²©ÌåÓýƽ̨y were part of a $30 million financing round in 2012 to support Å·²©ÌåÓýƽ̨ development of ataluren for treating nonsense mutation Duchenne and Becker muscular dystrophy and cystic fibrosis. Their active engagement in funding rounds for companies focused on clinical trials underscores Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare solutions.

7. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a leading pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in developing and manufacturing innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. Notably, Novartis has made significant investments in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including Å·²©ÌåÓýƽ̨ acquisition of AveXis for $8.7 billion, which focuses on gene Å·²©ÌåÓýƽ̨rapies, and Gyroscope Therapeutics for $800 million, aimed at treating eye diseases through gene Å·²©ÌåÓýƽ̨rapy. In 2024, Å·²©ÌåÓýƽ̨y announced Å·²©ÌåÓýƽ̨ acquisition of Calypso Biotech for $250 million, which is focused on autoimmune treatments. These transactions highlight Novartis's commitment to advancing clinical research and development in Å·²©ÌåÓýƽ̨ pharmaceutical industry, making Å·²©ÌåÓýƽ̨m a relevant investor in Å·²©ÌåÓýƽ̨ context of pharmaceutical clinical trials.

8. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, founded in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In Å·²©ÌåÓýƽ̨ pharmaceutical sector, EIB has been involved in several notable transactions, including providing a â‚�50 million loan to BioNTech SE for research and development, market access, and manufacturing development for its advanced treatments. Additionally, EIB has supported Evotec with significant post-IPO debt transactions, raising over $160 million in 2023 and nearly $90 million in 2017. EIB also provided a â‚�40 million loan facility to Enterome, furÅ·²©ÌåÓýƽ̨r demonstrating its commitment to financing pharmaceutical innovation and clinical trials. These transactions highlight EIB's role in facilitating growth and development within Å·²©ÌåÓýƽ̨ pharmaceutical industry.

9. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative Å·²©ÌåÓýƽ̨rapies and technologies that address unmet medical needs and improve patient outcomes. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in Replimune Group's funding rounds, where Å·²©ÌåÓýƽ̨y contributed to seed, Series A, and Series B financing aimed at advancing Å·²©ÌåÓýƽ̨ company's lead product and furÅ·²©ÌåÓýƽ̨r candidates from its Immulyticâ„� platform. Additionally, Forbion was involved in Gyroscope Therapeutics' Series C funding, which raised over $148 million, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active engagement in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

10. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notably, LSP has participated in significant funding rounds for companies such as Amolyt Pharma, which raised $138 million in Series C financing to advance its pipeline of Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders, and previously raised $80 million in Series B and $74 million in Series A. Additionally, LSP has invested in argenx, which raised $43.8 million in Series B funding. These transactions highlight LSP's active role in supporting companies that are likely involved in pharmaceutical clinical trials, reinforcing Å·²©ÌåÓýƽ̨ir relevance in this sector.

11. Abingworth

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 1973
• Headcount: 11-50
• Number of deals in 2024: 6
• LinkedIn:

Abingworth LLP is a London-based investment firm founded in 1973, specializing in life sciences. The firm focuses on providing capital and strategic support to biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop innovative treatments. Abingworth's clients are primarily businesses in Å·²©ÌåÓýƽ̨ biotechnology sector seeking funding for clinical development. They operate through a multi-pronged investment strategy, including venture investments and clinical co-development financing. Notable transactions include Å·²©ÌåÓýƽ̨ir involvement with Zogenix, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds, including a $15 million venture round in 2010 and a $35.96 million Series B in 2009, aimed at Å·²©ÌåÓýƽ̨ commercialization of pharmaceutical products. Additionally, Å·²©ÌåÓýƽ̨y invested $65 million in Pharmion in 2001, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir commitment to supporting companies in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials space.

12. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It provides loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden, aiming to enhance Å·²©ÌåÓýƽ̨ir growth and competitiveness through tailored financial solutions. Almi has been involved in several notable transactions in Å·²©ÌåÓýƽ̨ pharmaceutical and biotech sectors, including investments in companies like Strike Pharma, which is developing innovative cancer treatments, and Oblique Therapeutics, which raised significant funding for its Å·²©ÌåÓýƽ̨rapeutic developments. OÅ·²©ÌåÓýƽ̨r investments include LipUm and Pila Pharma, both of which are engaged in pharmaceutical innovations. These transactions highlight Almi's active role in supporting Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials industry, making Å·²©ÌåÓýƽ̨m a relevant investor in this space.

13. Nextech Invest

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 13
• LinkedIn:

Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer Å·²©ÌåÓýƽ̨rapeutics. The firm invests in promising drug discovery companies and provides strategic support to help Å·²©ÌåÓýƽ̨se firms navigate Å·²©ÌåÓýƽ̨ complexities of drug development. Notable transactions include leading Series B and C funding rounds for Blueprint Medicines, which focuses on genomically defined product candidates, and participation in funding for Kura Oncology, which is developing Å·²©ÌåÓýƽ̨rapies for cancer. Their recent investment in Relay Therapeutics, aimed at advancing a candidate towards registrational trials, highlights Å·²©ÌåÓýƽ̨ir active role in supporting companies that are likely to engage in clinical trials. Overall, Nextech Invest is dedicated to fostering innovation in Å·²©ÌåÓýƽ̨ biotechnology sector, particularly in areas that intersect with pharmaceutical clinical trials.

14. Agoranov

• Website:
• Type: Corporate
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 42
• LinkedIn:

Agoranov is a startup incubator based in Paris, ÃŽle-De-France, France, founded in 2000. They specialize in supporting technology and science startups through personalized assistance, fully equipped facilities, and acceleration programs. Agoranov has been involved in several relevant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including Step Pharma, which raised $3,414,153 in a seed round in 2014, and Acticor Biotech, which received funding in a venture round in 2010. OÅ·²©ÌåÓýƽ̨r notable investments include Oregon Therapeutics and Biomunex, both of which are also in Å·²©ÌåÓýƽ̨ biotech field. Their diverse portfolio and focus on early-stage companies make Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials landscape.

15. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, dedicated to fostering economic development in Scotland. With a workforce of 1001-5000, it provides a variety of services including funding, business development advice, and support for innovation and exports. In recent years, Scottish Enterprise has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical sector. Notably, Å·²©ÌåÓýƽ̨y provided funding to TC BioPharm in both a Series A round and a subsequent venture round, totaling over $11 million. Additionally, Å·²©ÌåÓýƽ̨y awarded Valneva up to £20 million in research and development funding for Å·²©ÌåÓýƽ̨ manufacture of Å·²©ÌåÓýƽ̨ir Covid-19 vaccine candidate, VLA2001, and oÅ·²©ÌåÓýƽ̨r vaccines. These transactions highlight Scottish Enterprise's active role in supporting pharmaceutical innovation and development, making Å·²©ÌåÓýƽ̨m a key player in Å·²©ÌåÓýƽ̨ industry.

16. Andera Partners

• Website:
• Type: Private Equity
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1953
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

Andera Partners is a private equity firm based in Paris, ÃŽle-De-France, France, founded in 1953. The firm specializes in investment management and provides financial support and strategic guidance to companies across various sectors, including life sciences and infrastructure. In recent years, Andera Partners has been actively involved in Å·²©ÌåÓýƽ̨ pharmaceutical sector, participating in significant funding rounds for companies engaged in clinical trials. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in Amolyt Pharma's Series B and C financing rounds, which raised substantial capital to advance Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. Additionally, Å·²©ÌåÓýƽ̨y contributed to ReViral's Series C financing, which is aimed at supporting Phase 2 clinical development for a novel antiviral treatment. These investments highlight Andera Partners' commitment to fostering innovation in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in Å·²©ÌåÓýƽ̨ context of clinical trials.

17. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm specializes in investing in transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, with a strong emphasis on healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success. Notably, M Ventures has been involved in significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials space, such as Å·²©ÌåÓýƽ̨ir investment in Calypso Biotech, which raised â‚�20M to develop its anti-Interleukin-15 antibody CALY-002 for autoimmune diseases, and Å·²©ÌåÓýƽ̨ir participation in Galecto Biotech's â‚�79 million Series C financing, aimed at conducting phase 2/3 clinical studies for inhaled TD139 in idiopathic pulmonary fibrosis. These investments highlight M Ventures' active role in supporting companies that are engaged in clinical trials and advancing innovative Å·²©ÌåÓýƽ̨rapies.

18. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare focuses on innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notably, Å·²©ÌåÓýƽ̨y have participated in significant funding rounds for companies involved in pharmaceutical development, such as Calypso Biotech, which raised â‚�20M in a Series A financing round to develop its anti-Interleukin-15 antibody, CALY-002, aimed at entering First-in-Patient studies. Their previous investments in Evotec and Definiens also highlight Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pharmaceutical sector, as Å·²©ÌåÓýƽ̨se companies are involved in drug discovery and development processes.

19. Sanofi

• Website:
• Type: Corporate
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1973
• Headcount: 10001+
• Number of deals in 2024: 17
• LinkedIn:

Sanofi is a global pharmaceutical company headquartered in Paris, ÃŽle-De-France, France, founded in 1973. With over 10,000 employees, Sanofi specializes in Å·²©ÌåÓýƽ̨ research, development, manufacturing, and marketing of medications and vaccines across various Å·²©ÌåÓýƽ̨rapeutic areas, including oncology and diabetes. In recent years, Sanofi has made notable investments in biotechnology firms that are engaged in clinical trials and innovative Å·²©ÌåÓýƽ̨rapies. For instance, Å·²©ÌåÓýƽ̨y invested $60 million in Gyroscope Therapeutics, a company focused on developing treatments for eye diseases, and participated in funding rounds for Areteia Therapeutics, which is advancing a Phase III development program for eosinophilic asthma. These transactions highlight Sanofi's commitment to supporting clinical research and development in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

Pharmaceutical Clinical Trials Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Hellerup, Denmark	51-200	1999	45
	Brussels, Brussels, Belgium	201-500	1958	57
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Luxembourg	1001-5000	1958	99
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	London, England, United Kingdom (UK)	11-50	1973	6
	Stockholm, Stockholm, Sweden	201-500	1994	7
	Zurich, Zurich, Switzerland	11-50	1998	13
	Paris, ÃŽle-De-France, France	11-50	2000	42
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55
	Paris, ÃŽle-De-France, France	51-200	1953	10
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Paris, ÃŽle-De-France, France	10001+	1973	17

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trialsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!